Investor Overview

Webcast ImageWebcast
Verastem Inc at Rodman & Renshaw 18th Annual Global Investment Conference (Live)
09/13/16 at 10:25 a.m. ET
Verastem Inc at Rodman & Renshaw 18th Annual Global Investment Conference
Tuesday, September 13, 2016 10:25 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem’s product candidates utilize a multi-faceted approach to treat cancer by reducing cancer stem cells, enhancing anti-tumor immunity, and modulating the local tumor microenvironment. The company’s most advanced clinical product candidates are the Focal Adhesion Kinase inhibitors, VS-6063 and VS-4718, and the dual PI3K/mTOR inhibitor, VS-5584.
Stock Quote
VSTM (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.42
Change (%) Stock is Up 0.04 (2.90%)
Volume720,054
Data as of 08/23/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News More >>
DateTitle 
08/08/16Verastem Reports Second Quarter 2016 Financial Results
BOSTON--(BUSINESS WIRE)--Aug. 8, 2016-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the second quarter ended June 30, 2016, and also provided an overview of certain corporate developments. “We continue to execute on the research and development of our two clinical-stage oncology programs targeting several high unmet need tumor types,” said Robert Forrester... 
Printer Friendly Version
07/06/16Verastem to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
BOSTON--(BUSINESS WIRE)--Jul. 6, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on Wednesday, July 13th at 3:30 PM Eastern Time at Le Parker Meridien New York. A live audio webcast of the presentation will be available on the company’s website at www.verastem.com. An archived presentation ... 
Printer Friendly Version
07/05/16Study Published in Nature Medicine Highlights Potential Role of FAK Inhibition in Pancreatic Cancer
- FAK Inhibition Renders Previously Unresponsive Pancreatic Tumors Responsive to Chemo- and Immunotherapy – - Preclinical Results Support Ongoing Phase 1 Clinical Trial in Patients with Pancreatic Cancer – BOSTON--(BUSINESS WIRE)--Jul. 5, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the publication of preclinical research in the journal Nature Medicine by the Company’... 
Printer Friendly Version
06/14/16Verastem Announces Changes to its Board of Directors
BOSTON--(BUSINESS WIRE)--Jun. 14, 2016-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced several changes to the Company’s Board of Directors. Michael Kauffman, MD, PhD, who has served as a director since November 2012, will become Lead Director and Bruce J. Wendel will join the Board as an independent director. “Bruce is a proven leader whose experience building companies and brin... 
Printer Friendly Version
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Verastem Inc posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.